George C Eckert Ii

Array ( [id] => 14005959 [patent_doc_number] => 10221419 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-05 [patent_title] => Fidgetin-like 2 as a target to enhance wound healing [patent_app_type] => utility [patent_app_number] => 15/917968 [patent_app_country] => US [patent_app_date] => 2018-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 6244 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15917968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15436173 [patent_doc_number] => 20200032270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => NUCLEIC ACID CAPABLE OF INHIBITING EXPRESSION OF MASP2 [patent_app_type] => utility [patent_app_number] => 16/491410 [patent_app_country] => US [patent_app_date] => 2018-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26306 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16491410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13566257 [patent_doc_number] => 20180334676 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => SPLICE MODULATING OLIGONUCLEOTIDES THAT INHIBIT CANCER [patent_app_type] => utility [patent_app_number] => 15/911975 [patent_app_country] => US [patent_app_date] => 2018-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15911975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16680745 [patent_doc_number] => 10940201 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-09 [patent_title] => Nucleic acid derivative having immunostimulatory activity [patent_app_type] => utility [patent_app_number] => 15/907920 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 15 [patent_no_of_words] => 41016 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15907920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13566255 [patent_doc_number] => 20180334675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => Culicinae Mosquito TRA-2 RNA Interference Technique to Genetically Produce Maleness Population [patent_app_type] => utility [patent_app_number] => 15/904548 [patent_app_country] => US [patent_app_date] => 2018-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 210 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15904548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14326977 [patent_doc_number] => 10294493 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same [patent_app_type] => utility [patent_app_number] => 15/904408 [patent_app_country] => US [patent_app_date] => 2018-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 4326 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15904408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14881547 [patent_doc_number] => 10420792 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Method of treating severe asthma [patent_app_type] => utility [patent_app_number] => 15/903505 [patent_app_country] => US [patent_app_date] => 2018-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 12379 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15903505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410073 [patent_doc_number] => 20180256579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING DRUG RESISTANCE IN CANCER [patent_app_type] => utility [patent_app_number] => 15/904176 [patent_app_country] => US [patent_app_date] => 2018-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15904176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17664060 [patent_doc_number] => 11357735 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => Particles and compositions comprising the same for transfection [patent_app_type] => utility [patent_app_number] => 16/484775 [patent_app_country] => US [patent_app_date] => 2018-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 10898 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15039271 [patent_doc_number] => 20190330640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => OLIGONUCLEOTIDES INHIBITING THE EXPRESSION OF NRP1 [patent_app_type] => utility [patent_app_number] => 16/476741 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16476741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14593967 [patent_doc_number] => 10350158 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-16 [patent_title] => 2' fluoro-modified RNAs as immunostimulators [patent_app_type] => utility [patent_app_number] => 15/860248 [patent_app_country] => US [patent_app_date] => 2018-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 26 [patent_no_of_words] => 8932 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15860248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14597333 [patent_doc_number] => 10351851 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-16 [patent_title] => Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells [patent_app_type] => utility [patent_app_number] => 15/855507 [patent_app_country] => US [patent_app_date] => 2017-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 14883 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15855507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300071 [patent_doc_number] => 20180201572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 15/846084 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15846084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16041149 [patent_doc_number] => 10682425 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-16 [patent_title] => Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them [patent_app_type] => utility [patent_app_number] => 15/841709 [patent_app_country] => US [patent_app_date] => 2017-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 48 [patent_no_of_words] => 39726 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15841709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15396237 [patent_doc_number] => 10538765 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-21 [patent_title] => Organic compositions to treat EPAS1-related diseases [patent_app_type] => utility [patent_app_number] => 15/834323 [patent_app_country] => US [patent_app_date] => 2017-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 51967 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15834323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527801 [patent_doc_number] => 20200056206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => CRISPR-BASED TREATMENT OF FRIEDREICH ATAXIA [patent_app_type] => utility [patent_app_number] => 16/464870 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16464870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15163689 [patent_doc_number] => 10487326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Peptide oligonucleotide conjugates [patent_app_type] => utility [patent_app_number] => 15/827431 [patent_app_country] => US [patent_app_date] => 2017-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 27 [patent_no_of_words] => 35467 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15827431 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13024677 [patent_doc_number] => 10034951 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2018-07-31 [patent_title] => Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity [patent_app_type] => utility [patent_app_number] => 15/820656 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 6044 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15820656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16475001 [patent_doc_number] => 10849921 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-01 [patent_title] => Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine [patent_app_type] => utility [patent_app_number] => 16/614439 [patent_app_country] => US [patent_app_date] => 2017-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 36364 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 254 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16614439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14897561 [patent_doc_number] => 20190292546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => TLR3 AGONIST FOR USE FOR INDUCING APOPTOSIS IN SENESCENT CANCER CELLS [patent_app_type] => utility [patent_app_number] => 16/348775 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3867 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348775 [rel_patent_id] =>[rel_patent_doc_number] =>)